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Abstract
Background: After a diagnosis of diabetes mellitus, people not only have to cope with the physical aspects and
common complications that require daily self-management, they are also faced with ongoing psychosocial challenges.
Subsequently they find themselves having to navigate the health system to engage multidisciplinary supports;
the combination of these factors often resulting in reduced health-related quality of life. To maintain optimal
diabetes control, interventions need to incorporate psychosocial supports and a skill base for disease management.
Therefore, our aim was to evaluate an ‘Optimal Health Program’ that adopts a person-centred approach and engages
collaborative therapy to educate and support the psychosocial health of people diagnosed with type I or II diabetes.
Methods: This prospective randomised controlled trial will include 166 people diagnosed with diabetes: 83 in the
intervention (Optimal Health Program) and 83 in the control (usual care) group. Participants with type diabetes mellitus
will be recruited through hospital outpatient clinics and diabetes community organisations. Participants in the
intervention group will receive nine (8 + 1 booster session) sequential sessions, based on a structured treatment manual
emphasising educational and psychosocial support self-efficacy and skills building. The primary outcome measures will
be generalised self-efficacy (GSE) and health-related quality of life (AQoL-6D and EQ-5D). Secondary measures will be
anxiety and depression (HADS), social and workplace functioning (WSAS), diabetes-related quality of life (DQoL),
diabetes-related distress (PAID), and type of coping strategies (Brief COPE). In addition, a health economic cost
analysis and process evaluations will be performed to assess the economic cost and efficacy of the program’s
operations, implementation and service delivery.
Discussion: We envisage that the Optimal Health Program’s emphasis on self-efficacy and self-management will
provide participants with the skills and knowledge to achieve increased empowerment and independence in
aspects of health, which in turn, will help participants deal more effectively with the physical and psychosocial
complexities of diabetes.
Trial registration: ACTRN12614001085662. Registered on 10 October 2014.
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Background
There are an estimated 382 million people globally with
diabetes mellitus (DM) − a prevalence of 8.3 % [1]. Far
more people are estimated to have blood glucose levels
in the prediabetes range, with an increased risk for type
2 diabetes, placing a significant proportion of the world’s
population at risk of developing devastating diabetes
complications [2]. Diabetes is usually incurable and re-
quires daily and complex self-management; and atten-
tion to psychological issues is pivotal to achieving
optimum health outcomes [3]. Psychological disorders,
including depression, anxiety, maladjustment and eating
disorders are highly prevalent in children and adults
with DM and are associated with poor prognosis [4–8].
Recognition of such concerns has prompted the incorp-
oration of psychological aspects of DM in national stan-
dards of care [4, 9].
At the centre of diabetes care is maintaining optimal
glucose target ranges. This is highly reliant on a person’s
successful negotiation of healthcare systems and coordin-
ation with clinicians [10]. Even when blood glucose levels
are within targets, hypoglycaemia can contribute to fear,
anxiety and has been associated with decreased quality of
life [11]. Emerging evidence suggests that severe nocturnal
hypoglycaemia is linked to ‘dead in bed’ syndrome, re-
sponsible for approximately 6 % of deaths in people with
diabetes aged less than 40 years of age [12]. Understand-
ably, fear of hypoglycaemia is common and difficult to dis-
tinguish from anxiety given the shared symptoms e.g.,
pounding heart, sweating. Improving awareness of anxiety
as distinct from hypoglycaemia may encourage persons
with diabetes to respond more rapidly, potentially averting
a severe episode of illness [11].
Similarly, depression and diabetes have an overlapping
relationship, lending further support for holistic programs
that facilitate exploration of physical and emotional
domains of health. On a biological level, one hypothesis is
that depression (which often co-occurs with anxiety) is
associated with glucose metabolism via activation of the
hypothalamic–pituitary–adrenal cortical (HPA) axis,
though the specificity of this link to depression versus
other psychiatric conditions is unclear [13]. People who
are depressed may also have low motivation and energy,
adversely impacting diabetes self-management tasks. Vice
versa, if diabetes self-care is challenged, or a person be-
comes increasingly hopeless about developing complica-
tions, a depression presentation can arise. Depression can
also present in the context of direct mood effects of
chronic hyperglycaemia (high blood sugar).
This evidence highlights the bi-directional relation-
ships between diabetes and mental health, present across
the spectrum from mild to more severe clinical presen-
tations. Through supporting emotional wellbeing, it is
clear to see how improvements in diabetes can follow,
and vice versa, with good support. This randomised con-
trolled trial (RCT) of Mental Health in Diabetes Services
Optimal Health Program (MINDS OHP) will adopt a
person-centred approach combining collaborative ther-
apy and care coordination to support and improve the
psychosocial health of people living with DM.
Diabetes psychosocial interventions
Diabetes is a challenging condition due to the complex
interactions between physiological, psychological and
environmental factors and its evolving nature [14, 15].
Recently, interventions and guidelines have minimised
advocacy of a hierarchical clinician/patient relationship
in favour of a collaborative approach to be delivered by a
multidisciplinary team that tailors interventions to each
individual’s situation [4, 9, 16]. As such, shared decision
making, pragmatic problem solving and promotion of
behaviour change strategies are integral to achieving sus-
tainable self-management of DM [4, 5]. Growing evi-
dence has been presented for the use of psychosocial
interventions in people with DM, yet questions regard-
ing their efficacy remain [17].
A recent RCT that assessed the effectiveness of cogni-
tive behaviour therapy (CBT) to improve glycaemic con-
trol and psychosocial wellbeing in adolescents with type
1 DM (n = 147), demonstrated little improvement in gly-
caemia [18], but improvements in psychosocial wellbeing
(self-efficacy and quality of life) were shown at 3- and
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12-month follow-up. Challenges were also noted in the
integration of psychosocial services into clinical care, in-
cluding cost-effectiveness issues, intervention participa-
tion, acceptance and attrition [18].
A systematic review and meta-analysis of psychother-
apy, antidepressant medication and collaborative care for
comorbid DM and depression (14 RCTs; n = 1724)
showed that pharmacotherapy and collaborative care re-
duced depressive symptoms; however, with the exception
of sertraline, there was no effect on glycaemic control
[5]. The authors concluded that collaborative care con-
taining psychological and pharmacological components
is of considerable clinical relevance, although a strong
emphasis on DM management and further research into
type 1 DM specifically is warranted [5].
A Cochrane review of psychological and pharmaco-
logical interventions for depression in DM (eight
RCTs; n = 1122) found a moderate and clinically signifi-
cant effect on depression [6]. Also noted was sparse and
inconclusive evidence in relation to the influence of psy-
chological intervention on blood glucose levels, largely
due to substantial risk of bias and heterogeneity of popu-
lations and interventions [6]. Similar findings regarding
CBT and glycaemic control in DM were also reported in
another systematic review and meta-analysis (eight stud-
ies; n = 1547), which revealed a non-significant trend to-
wards improved blood sugar levels (BSLs) [19].
Recent evidence has established that effective disease
management of DM requires strengthening of psycho-
social skills, ideally within a collaborative therapy frame-
work integrated with usual medical care [4, 5, 16]. A
number of challenges have also been noted including:
cost-effectiveness, participation and attrition rates, and
delivery that complements and coexists with usual DM
health care [6, 17, 18]. As DM has reached epidemic
proportions [1]; new and innovative ways of managing it
are essential. The MINDS Optimal Health Program
(MINDS OHP) adopts a collaborative therapy approach
that offers structured yet individualised multidisciplinary
support and education to enhance self-efficacy and the
psychosocial wellbeing of people with type 1 and type 2
DM. The program recognises that though there are
shared psychosocial impacts, type 1 and type 2 diabetes
have separate aetiologies and disease processes which
will be taken into account in delivering and evaluating
the MINDS OHP.
Translating Research, Integrated Public Health Outcomes
and Delivery (TRIPOD)
This RCT is part of a larger research program, TRIPOD,
which will evaluate our OHP across three chronic condi-
tions −DM, stroke and chronic kidney disease − inclusive
of cost-effectiveness analyses. Based on a collaborative
therapy framework [20], the OHP was originally
developed to support people with mental illness [21, 22].
An earlier trial of OHP in an Australian adult mental
health service demonstrated significant improvements in
health and social functioning, a reduction in hospital ad-
missions and net cost savings of AU$6,000 per patient an-
nually [22]. A key aspect of collaborative therapy is
recognising that ‘recovery’ and models of chronic health
care are not dichotomous [22]. With the intention of en-
hancing self-efficacy, self-management, care coordination
and quality of life, the OHP has been adapted within the
broader context of chronic disease. Thus, in the current
series of trials our OHP is used to implement this thera-
peutic framework to enable clinicians and consumers to
work systematically towards the achievement of optimal
mental health outcomes within mainstream services. The
self-management foundations of the OHP are particularly
relevant for adults with DM who face the daily challenge
of managing often simultaneous aspects of their disease
such as diet, exercise, insulin delivery, carbohydrate
counting, and blood glucose monitoring, as well as cop-
ing with the emotional impact of their condition and
care regimen. This protocol describes an RCT (MINDS
OHP) that has been designed to evaluate the OHP for
people living with DM.
Pilot study: clarifying the experience of insulin pump users
Adaptation of the OHP for people with DM was in-
formed by anecdotal evidence, a review of the associated
literature, and pilot data. Preliminary work to inform the
content and structure of the MINDS manual compro-
mised focus groups of adults with T1DM (two focus
groups; n = 3, n = 2, and one individual participant inter-
view) that specifically explored the adaptability of the
OHP to DM. The six domains of health from the ‘Opti-
mal Health Wheel’ used in the original OHP were used
to guide the direction of discussions (Fig. 1, inner circle).
The Framework Method was deemed appropriate to
analyse the qualitative content of the focus group data
as it provides a systematic model for identifying themes
via managing and mapping the data [23]; a specific area
of interest was how people dealt with insulin pump
therapy [24, 25].
Findings from the focus groups highlighted the im-
portance of self-perception in living and coping with
DM. The emotional domain dominated focus group dis-
cussions; key themes identified were: a sense of helpless-
ness in gaining control over DM, flexibility of the pump
in daily lifestyle; pump malfunction; low self-esteem and
self-efficacy regarding adequate management of blood
glucose levels; and ongoing concerns about similar ‘out
of their control’ experiences in the future. These findings
highlight the need for psychosocial supports in the man-
agement of DM, especially in regard to self-reflection,
problem solving and stress management. Self-efficacy is
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at the centre of OHP and it is therefore well-placed to
support those living with DM. A summary of the find-
ings/themes identified by people with DM associated
with each of the Optimal Health Wheel domains are
presented in Fig. 1 (see Fig. 1, outer circle).
Research aims
The aim is to determine whether a DM-specific OHP
(MINDS OHP) will improve the psychosocial health of
people with diabetes, compared to usual care. The pri-
mary objective is to identify the impact of the OHP on
levels of self-efficacy and quality of life for those living
with DM. Secondary objectives are to evaluate the im-
pact of the OHP on depression, anxiety, social and work-
place functioning, diabetes-related distress, illness
perceptions of DM, and coping with DM.
In addition, a health economic cost analysis will be
performed, assuming an Australia-wide implementation,
to identify any cost savings of the MINDS OHP inter-
vention over current practice. Quality-adjusted life years
(QALYs) will be measured using the Assessment of
Quality of Life-6D (AQoL-6D) [26] and European Quality
of Life-5 dimensions (EQ-5D) [27]. Process evaluation in-
cluding focus group interviews will also be conducted with
participants with diabetes and diabetes clinicians to assess
the effectiveness of the MINDS OHP operations, imple-
mentation, and service delivery.
Methods
General design
This is a prospective randomised controlled trial exam-
ining the effectiveness of the OHP specifically adapted
for adults with DM, focused on improving participants’
psychosocial health.
The intervention period lasts for 8 weeks with an add-
itional booster session, and is compared with usual care.
The study protocol and its amendments were approved by
the Human Research Ethics Committee of St Vincent’s
Hospital Melbourne (decision number 036/14, 21 April
2015). An executive steering committee (all authors) is re-
sponsible for study planning, conduct and monitoring.
Setting
The study will be conducted at St Vincent’s Hospital, a
large metropolitan teaching hospital in Melbourne,
Australia. As of March 2015 the endocrinology and dia-
betes unit had over 1000 people with diabetes enrolled
in their patient database: 370 people with type I DM and
1313 with type 2 DM. The necessary volume of clinical
cases and expertise required for this study is well
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Fig. 1 Optimal Health Program (OHP) Optimal Health Wheel (inner circle) and diabetes mellitus (DM) pilot study findings (outer circle)
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established in this unit. As a focus of the OHP is care
co-ordination, the program has been integrated into
existing services through transparent, planned and close
collaboration with the diabetes unit, i.e. diabetes educa-
tors, endocrinologists, social workers, and dieticians.
Participants
A total of 166 participants with a diagnosis of DM will
be recruited into the RCT. Inclusion criteria are: (1) have
a DM diagnosis, confirmed by medical records; (2) be
aged 18 years or above; and (3) be able to converse in
English without an interpreter. Exclusion criteria are: (1)
presence of developmental disability or amnestic syn-
drome impairing their ability to learn from the interven-
tion; and (2) comorbid serious acute medical illness
defined by the treating physician. As the OHP adopts a
holistic approach to managing chronic disease, patients
may enter the program at any stage along the continuum
of care. De-identified records will be collected on how
many people with diabetes were approached or self-
referred to the study including reasons for decline, to as-
sess for potential selection bias.
Power was calculated to detect a medium effect size of
d = 0.50. This was chosen as a clinically meaningful ef-
fect size that may be compared with previous RCT re-
search in the area of chronic disease management
programs [28]. The calculations assumed two primary
outcomes (health-related quality of life and General Self-
efficacy Scale (GSE) scores), four assessment points
(baseline, 3-month, 6-month, and 12-month follow-ups),
a study-wide type I error rate (α) of .05, and hence a
type II error rate (β) of 0.20 (power of 0.80), a correl-
ation of post-treatment scores with baseline measure-
ments (ρ) of 0.81, and a two-tailed statistical test [29].
To detect the effect size of d = 0.50, 66 participants in
each of the control and intervention groups will be re-
quired. Allowing for up to 20 % attrition, a total of 166
participants, or 83 in each group will be recruited.
Study procedures
Consent
The process of consent will be in accordance with the
Declaration of Helsinki. All eligible people with diabetes
will be fully informed that they are being asked to par-
ticipate in an RCT. The procedures involved in the
study, and the chances of being assigned randomly to
one of two groups will be explained verbally and via an
information sheet approved by St Vincent’s Hospital
Human Research Ethics Committee. A signed consent
form will be obtained from each participant. Participants
will be made aware of their right to withdraw from the
study at any time without any effects on their usual clin-
ical management.
Randomisation and blinding
Using a computer-generated block randomisation se-
quence created by a person not directly involved in the
study, participants will be allocated to treatment or con-
trol group. The allocation sequence will be generated
using random numbers. Participants will be randomised
progressively as they consent. Due to the nature and
length of the intervention, it is not possible to mask either
participant or investigator to the treatment allocation.
Recruitment
Potential participants with DM at St Vincent’s Hospital
will be identified by the diabetes clinical staff (e.g. endo-
crinologist, diabetes educator) and provided with a study
flyer. People with diabetes will be asked permission for a
researcher to approach them to discuss the program in
more detail. If agreeable, people with diabetes will be
approached, informed and formally consented by the re-
search assistant. Study flyers will also be posted online
through community organisations and will include con-
tact details for the research team. Participants from the
community may contact researchers directly to request
further information. Recruitment will occur over an 18-
month period (see Fig. 2).
Intervention: MINDS OHP
The MINDS OHP is delivered in nine (8 + 1 booster ses-
sion) sequential sessions based on a structured treat-
ment manual Optimal Health Program: My Workbook
(version 3) [30]. The sessions will be one-on-one, deliv-
ered face-to-face, and participants in rural and regional
areas will have the option of participating in sessions via
videoconferencing or telephone. Participants are encour-
aged throughout the program to identify which areas of
DM other health domains upon which they would like
to focus. Sessions are approximately 1 hour in duration
and held weekly, apart from the ‘booster’ session, which
is held 3 months after session 8. Learning is cumulative
with each session designed to build on the previous ses-
sion including tasks to complete between sessions, such
as journaling and sleep logs.
In summary, session 1 introduces the OHP within the
six domains of the Optimal Health Wheel: social, phys-
ical, emotional, intellectual, employment (engagement)
and spiritual/values. This session provides participants
with the opportunity to explore and understand their
DM and other health priorities from a holistic perspec-
tive. Sessions 2 and 3 initiate development of a health
plan exploring the implications and potential complica-
tions of DM in terms of strengths and vulnerabilities. In
session 3, further understanding is developed around the
effects of stress or blood glucose levels with strategies to
mitigate these stressors and informing their health plans.
Session 4 focuses on metabolic monitoring and medication
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management (e.g. use of insulin pumps). Session 5 expands
the health plan to include key DM partnerships and sup-
ports in the community and online, for example Diabetes
Australia [31], and HypoActive [32]. Change enhancement
is the focus in session 6, in terms of understanding past
events and establishing new proactive avenues for change.
The aim of session 7 is goal setting via creative problem
solving and planning around the complexities of DM.
Session 8 strategises DM health and emergency care
planning that incorporates wellbeing maintenance and
sustainability. The goal of the ‘booster session’ (session
9) is to review health plans, consolidate progress, and
reflect on achievements towards health-related goals.
A facilitator with a health background (e.g., nurse,
psychologist) will conduct each session. All facilitators
will complete a 2-day workshop plus regular supervision
and fidelity checks. Facilitators will draw on DM-specific
information in concordance with individual circum-
stances. Examples include the relationship between
stress and hypoglycaemia, availability of DM supports in
the community, and coping strategies for addressing
anxiety related to changes in BSLs. The emphasis is on
collaboration between facilitator and participant to ar-
rive at program goals that stem from the participant’s
main concerns and needs. The facilitator will encourage
participants to identify their early warning signs of stress
and illness and integrate healthy coping strategies to
prevent stress build-up. Facilitators may also discuss and
arrange referrals for other services in conjunction with
the multidisciplinary team depending on participant
needs. Additionally, facilitators may work with the
multidisciplinary team to coordinate visits with other
hospital appointments.
Control
The comparison group will receive usual care and no
MINDS OHP intervention. As participants will be re-
cruited from a variety of settings (hospital outpatients,
Inclusion criteria met
Informed consent and baseline assessment
Randomization
OHP Intervention n=83 Control group (usual care) n=83
3-month follow-up assessment 
Assessment of eligible people with DM
6-month follow-up assessment 
12-month follow-up assessment
Excluded from study
Declined to participate
Fig. 2 Flowchart of the Mental Health in Diabetes Services Optimal Health Program (MINDS OHP) randomised controlled trial (RCT)
O’Brien et al. Trials  (2016) 17:444 Page 6 of 10
community organisations) we anticipate variation in
standard care received. To capture this variation, all
participants will complete the Health Care Utilisation
Questionnaire (HCUQ) [33] at each time point. Partici-
pants in the control group will have the option of com-
pleting the MINDS OHP at the end of the trial once
evaluation is complete.
Outcome measurements
Table 1 displays primary and secondary outcome mea-
sures and time points. Primary measures are changes in:
health-related quality of life as assessed by the AQoL-6D
[26], consisting of six separately scored dimensions of
good health and a simple global ‘utility’ score and EQ-
5D [27]; and self-efficacy as measured by the General
Self-Efficacy Scale (GSE) [34], a general sense of per-
ceived self-efficacy in regarding daily hassles as well as
adaptation to stressful life events. Secondary measures
are: the Diabetes Quality of Life (DQoL) [35] measure, a
screen for problem or risky substance use in adults as
assessed by the Alcohol, Smoking and Substance
Involvement Screening Test (ASSIST) [36] developed by
the World Health Organization (WHO); coping
strategies as measured by an abbreviated version of the
COPE inventory [37], the Brief COPE [38]; treatment ex-
pectancy and rationale credibility in clinical studies as
assessed by the Credibility/Expectancy Questionnaire
(CEQ) [39]; clinical indices such as body mass index
(BMI) and glycated haemoglobin (HbA1c); diabetes-
related psychosocial self-efficacy measured by the
Diabetes Empowerment Scale (DES) [40]; symptom se-
verity and caseness (number meeting clinical disorder
threshold) of anxiety and depression as assessed by the
Hospital Anxiety and Depression Scale (HADS) [41];
health care utilisation for economic evaluation purposes
assessed by the Health Care Utilisation Questionnaire
(HCUQ) [32]; diabetes-related emotional distress mea-
sured by the Problem Areas in Diabetes Scale (PAID)
[42]; perceived acceptability of treatment assessed using
the Treatment Evaluation Inventory-Short Form (TEI-SF)
[43]; a 10-item measure of the Big Five Inventory (BFI)
personality dimensions [44]; and impact of a person’s
mental health difficulties on their ability to function via
the Work and Social Adjustment Scale (WSAS) [45].
Due to variability of usual care across all participants,
key aspects of usual care will be assessed via responses
on the HCUQ [32]. If possible, medical records will be
reviewed to ascertain DM diagnostic information and
clinical indicators such as HbA1c.
Program assessment and treatment fidelity
The OHP facilitators will receive training, a structured
manual/protocol, and monthly group supervision with
the clinical investigators (with individual supervision
provided as needed in between group sessions). The pur-
pose of supervision will be to discuss problems in study
procedures and ensure standardised activity. The OHP
sessions will be audio recorded with a random selection
rated by independent assessors according to compliance
with OHP protocols. Identified variations from protocols
will be communicated back to the facilitator. In addition,
content of sessions including participant needs and con-
cerns will be raised at supervision meetings. All facilita-
tors will complete a summary of each session using a
standard template and send these notes to the research
team. Session notes will include OHP topics covered,
participant concerns raised, and needs for supervision.
Post-intervention focus groups will be held for clini-
cians and for participants from the control and interven-
tion groups. Participants will be informed that the
purpose of the focus group is to gain an in-depth under-
standing of their experiences of the study, advantages
and disadvantages of conducting the study/program in
their services (for service providers), and suggestions for
components to include or exclude from the OHP. To in-
crease objectivity, focus group facilitators will be inde-
pendent researchers who were not OHP facilitators.
Table 1 Primary and secondary outcome assessments and time
points for MINDS
Assessment tools Baseline 3-month 6-month 12-month
Primary outcomes
AQoL-6D (20 items) X X X X
GSE (10 items) X X X X
Secondary outcomes
DQoL (15 items) X X X X
ASSIST (6 items) X X X X
Brief COPE (28 items) X X X X
CEQ (6 items) X
Clinical Indices (e.g. BMI) X X X X
DES (8 items) X X X X
EQ-5D-3L (6 items) X X X X
HADS (14 items) X X X X
HCUQ (17 items) X X X X
PAID (20 items) X X X X
TEI-SF (9 Items) X
BFI-10 (10 items) X
WSAS (5 items) X X X X
AQoL-6D Assessment of Quality of Life-6 Dimensions [26], GSE General Self-
efficacy Scale [34], DQoL Diabetes Quality of Life [35], ASSIT Alcohol, Smoking
and Substance Involvement Screening Test [36], Brief COPE abbreviated version
of the COPE Inventory [38], CEQ Credibility/Expectancy Questionnaire [39], BMI
body mass index, DES Diabetes Empowerment Scale [40], EQ-5D-3L European
Quality of Life-5 Dimensions-3 Levels [27], HADS Hospital Anxiety and Depres-
sion Scale [41], HCUQ Health Care Utilisation Questionnaire [33], PAID Problem
Areas in Diabetes Scale [42], TEI-SF Treatment Evaluation Inventory-Short Form
[43], BFI-10 Big Five Inventory-10 item [44], WSAS Work and Social Adjustment
Scale [45]
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Statistical analyses
Intention-to-treat analyses will be employed to prevent
overestimation of efficacy. Categorical variables will be
analysed using chi-squared tests (or Fisher’s exact test
for small samples). A mixed-effects model, repeated
measures (MMRM) approach will be used to examine
the longitudinal profile of all continuous variables at 3, 6
and 12 months post-baseline. For all MMRM analyses,
baseline scores will be used as covariates and the models
will include prespecified fixed effects of treatment, clin-
ician, and time, and treatment-by-time and treatment-
by-clinician interactions.
Secondary analyses using analysis of covariance will be
conducted to compare change scores during treatment
and follow-up phases for all primary, secondary, and
process outcomes using the fixed, continuous covariate
of baseline score and time from diagnosis as well as the
categorical fixed effects of treatment group, clinician,
and treatment-by-clinician interactions. Sub-analyses
will be conducted on participants with T1 and T2DM as
these have different disease processes and aetiologies.
Although the attrition rate is not expected to vary
by treatment condition, we will attempt to identify
key predictors of attrition status (i.e. demographic
and baseline clinical characteristics) and test for dif-
ferences between conditions. Assuming the data are
missing at random, several procedures offer effective
approaches that may attenuate attrition. Maximum
likelihood models (i.e. MMRM), with time as a ran-
dom variable, allow the use of all available data from
all assessments, reducing bias and increasing power
[46]. In addition, multiple imputation procedures that
utilise the expectation-maximization (EM) algorithm
with bootstrap estimates of standard errors will be
used to address attrition. The application of these
procedures can provide unbiased estimates, even in
the face of substantial missing data [47].
A full economic evaluation will occur alongside the
proposed RCT. Healthcare outcomes and costs will be
compared between participants in control and interven-
tional conditions. Healthcare system (medical record)
and self-reported information via the HCUQ [32] will be
used to generate analyses. The utility measurements of
participant quality of life will be assessed using AQoL-6D
[26] developed in Australia and the EQ-5D-3L [40] devel-
oped in Europe. The potential long-term (lifetime) impact
on cost and effectiveness of intervention beyond the trial
period will be extrapolated using the Markov process
modelling method.
Discussion
Diabetes is a multifaceted chronic disease that places
many at high risk of developing diabetes-related compli-
cations and conditions when management is not within
optimal target ranges [2]. The complexity of DM in-
creases due to the impact on psychosocial health and
the necessity of navigating the health system for not
only physical but also psychological purposes [3–8].
To our knowledge, this will be the first trial to test a
collaborative therapy OHP integrated in the clinical
setting that focuses on the psychosocial health of
people living with DM. We investigate in our trial the
effects of an 8-week psychosocial intervention to im-
prove self-efficacy, self-management and quality of life
of people living with DM.
The MINDS OHP has several strengths, primarily the
recognition for coordinated care aimed at enhancing the
wellbeing of people experiencing chronic disease. The
emphasis on self-efficacy and self-management fosters
health promotion as it provides the patient with the
basic building blocks to take control of their illness and
recovery. By working towards this shift in focus of the
person’s illness from being ‘dependent on’ services to be-
ing ‘supported by’ services, the MINDS OHP provides
enablers for increased independence and empowerment.
If the findings are positive, we envisage that the OHP
will be translated into the hospital’s clinical pathway for
referral and engagement across all chronic diseases, as
well as included as a core component of educational
training accessible to all staff. In addition the quality
control component of this trial, via process evaluation,
will offer further insight into how the intervention can
best be adapted and integrated into the general medical
or community setting.
We believe that this innovative trial will contribute to
the knowledge of interventions aimed at supporting
people with DM and broaden the focus from symptoms
to include psychosocial factors such self-efficacy, well-
being and community supports.
Trial status
Patient recruitment commenced April 2015 and data
collection will continue until at least December 2017.
ANZCTR no. 12614001085662
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